H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Sage Therapeutics (SAGE) to $14 from $25 and keeps a Neutral rating on the shares. The firm is encouraged to see the progress that Sage have made with the launch of Zurzuvae. It cites the company’s narrowing of the pipeline focus for the target cut.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics Reports Q3 Growth and Strategic Focus
- Sage Therapeutics reports Q3 EPS ($1.53) , consensus ($1.53)
- SAGE Therapeutics, Inc. (US) (SAGE) Q3 Earnings Cheat Sheet
- Sage Therapeutics Restructures Amid Leadership Changes and Cost Cuts
- Sage Therapeutics to reduce workforce by 33%, prioritize Zurzuvae